Compare · RDUS vs SNN
RDUS vs SNN
Side-by-side comparison of Radius Recycling Inc. (RDUS) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- RDUS operates in Consumer Discretionary, while SNN operates in Health Care - the two are in different parts of the market.
- SNN is the larger of the two at $12.89B, about 38.3x RDUS ($336.1M).
- Over the past year, RDUS is up 1.3% and SNN is up 1.6% - SNN leads by 0.3 points.
- SNN has hit the wire 12 times in the past 4 weeks while RDUS has been quiet.
- SNN has more recent analyst coverage (23 ratings vs 18 for RDUS).
- Company
- Radius Recycling Inc.
- Smith & Nephew SNATS Inc.
- Price
- $30.00+0.02%
- $30.35-0.85%
- Market cap
- $336.1M
- $12.89B
- 1M return
- +1.32%
- +0.96%
- 1Y return
- +1.32%
- +1.61%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 12
- Recent ratings
- 18
- 23
Radius Recycling Inc.
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest RDUS
- SEC Form 15-12G filed by Radius Recycling Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Radius Recycling Inc.
- Director Hunter Rhonda D returned $1,357,619 worth of shares to the company (45,254 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- Chairman, President & CEO Lundgren Tamara L. returned $38,365,800 worth of shares to the company (1,278,860 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- SVP, CFO Gaggini Stefano R. returned $2,708,430 worth of shares to the company (90,281 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- SVP, Chief HR Officer Erich Wilson D returned $1,785,900 worth of shares to the company (59,530 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- EVP & COO Hathhorn Marc E. returned $4,367,430 worth of shares to the company (145,581 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- SVP & President, Recycling P&S Heiskell Steven returned $4,174,800 worth of shares to the company (139,160 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- Director Friedman Gregory R returned $562,186 worth of shares to the company (18,740 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- Director Shoemaker Leslie L returned $600,507 worth of shares to the company (20,017 units at $30.00), closing all direct ownership in the company (SEC Form 4)
Latest SNN
- Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith & Nephew downgraded by Kepler
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching
- SEC Form SD filed by Smith & Nephew SNATS Inc.